Adipocytes Encapsulating Telratolimod Recruit and Polarize Tumor-Associated Macrophages for Cancer Immunotherapy

Adv Sci (Weinh). 2023 Feb;10(5):e2206001. doi: 10.1002/advs.202206001. Epub 2022 Dec 16.

Abstract

Tumor-associated adipocytes (TAAs) recruit monocytes and promote their differentiation into tumor-associated macrophages (TAMs) that support tumor development. Here, TAAs are engineered to promote the polarization of TAMs to the tumor suppressive M1 phenotype. Telratolimod, a toll-like receptor 7/8 agonist, is loaded into the lipid droplets of adipocytes to be released at the tumor site upon tumor cell-triggered lipolysis. Locally administered drug-loaded adipocytes increased tumor suppressive M1 macrophages in both primary and distant tumors and suppressed tumor growth in a melanoma model. Furthermore, drug-loaded adipocytes improved CD8+ T cell-mediated immune responses within the tumor microenvironment and favored dendritic cell maturation in the tumor draining lymph nodes.

Keywords: adipocyte; cancer immunotherapy; drug delivery; macrophage.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adipocytes / pathology
  • Humans
  • Immunotherapy
  • Macrophages
  • Melanoma*
  • Tumor Microenvironment
  • Tumor-Associated Macrophages*